The FDA on June 27, 2018 approved BRAFTOVI® and MEKTOVI® in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI® and MEKTOVI® are products of Array BioPharma Inc.
Bottom Ad
Advertisement
Subscribe
